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Abstract
Background: Mucosa-associated Escherichia coli are frequently found in the colonic mucosa of patients with colorectal
adenocarcinoma, but rarely in healthy controls. Chronic mucosal E. coli infection has therefore been linked to colonic
tumourigenesis. E. coli strains carrying eae (encoding the bacterial adhesion protein intimin) attach intimately to the
intestinal mucosa and are classed as attaching and effacing E. coli (AEEC). Enteropathogenic Escherichia coli (EPEC) are the
most common form of AEEC identified in man. EPEC utilise a type III secretion system to translocate effector proteins into
host cells and infection induces wide-ranging effects on the host cell proteome. We hypothesised that EPEC infection could
influence molecular pathways involved in colorectal tumourigenesis.
Methodology/Principal Findings: When co-cultured with human colorectal cell lines, EPEC dramatically downregulated the
expression of key DNA mismatch repair proteins MSH2 and MLH1 in an attachment specific manner. Cytochrome c staining
and TUNEL analysis confirmed that this effect was not a consequence of apoptosis/necrosis. Ex vivo human colonic mucosa
was co-cultured with EPEC and probed by immunofluorescence to locate adherent bacteria. EPEC entered 10% of colonic
crypts and adhered to crypt epithelial cells, often in the proliferative compartment. Adenocarcinoma and normal colonic
mucosa from colorectal cancer patients (n = 20) was probed by immunofluorescence and PCR for AEEC. Mucosa-associated
E. coli were found on 10/20 (50%) adenocarcinomas and 3/20 (15%) normal mucosa samples (P,0.05). AEEC were detected
on 5/20 (25%) adenocarcinomas, but not normal mucosa samples (P,0.05).
Significance/Conclusions: The ability of EPEC to downregulate DNA mismatch repair proteins represents a novel gene-
environment interaction that could increase the susceptibility of colonic epithelial cells to mutations and therefore promote
colonic tumourigenesis. The potential role of AEEC in colorectal tumourigenesis warrants further investigation.
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Introduction
Colorectal cancer is responsible for nearly half a million deaths
annually, and over 940,000 new cases are diagnosed worldwide
each year [1]. Despite the characterisation of many aetiologic
genetic changes – such as mutation of APC and genes encoding
DNA mismatch repair proteins – the specific causative factors in
the development of sporadic colorectal cancer remain unclear.
Gene-environment interactions have a significant influence on the
susceptibility to colorectal cancer, but our current understanding
of these interactions is limited [2].
Bacteria contribute significantly to the colonic environment and
chronic bacterial infection has been linked to colonic tumourigen-
esis [3]. Studies on cancer patients in the UK and Germany reveal
that mucosa-associated bacteria are more frequently identified in
colon tissue from patients with adenocarcinomas than in controls
[4,5]. Swidsinski et al. report that only 3% of colon mucosa biopsies
from asymptomatic controls tested positive for bacteria. In
contrast, biopsies from 92% of patients with colonic adenomas
or carcinomas held bacteria, with Escherichia coli the predominant
bacteria in 70% of patients [5]. Similarly, Martin et al. found that
70% of colorectal cancer patients had mucosa-associated bacteria,
and that a significant proportion of the bacterial isolates were E.
coli strains that adhered to HT29 cells in vitro [4]. These studies
clearly demonstrate a link between mucosally adherent E. coli and
colon cancer. Whether this relationship is a cause or effect of
tumourigenesis is an important question that is yet to be resolved.
Bacteria that carry the eae gene, which encodes the bacterial
adhesion protein intimin, are able to attach intimately to the
intestinal epithelium and are classified as attaching and effacing
(AE). The eae gene is carried by enteropathogenic E. coli (EPEC),
enterohemorrhagic E. coli (EHEC), E. albertii and Citrobacter
rodentium strains, and is not carried by E. coli strains characterised
as belonging to the normal human microflora [6]. EPEC is the
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most commonly identified AE bacteria in man and is a major
cause of potentially fatal infantile diarrhoea in developing
countries [7]. In developed countries the incidence of EPEC
induced diarrhoea has declined, consequently routine screening
for EPEC is no longer performed [6]. However, recent studies in
Europe and Australia have identified EPEC in 2.5–10.9% of
healthy children and (in one study) children and adults [8–11],
suggesting that a significant percentage of the healthy population
in developed countries harbour EPEC within their gastrointestinal
microflora. The inability to identify certain strains of EPEC in
animals supports the conclusion that man is a natural reservoir for
EPEC [7]. Although acute EPEC infection is known to cause
diarrhoea, the effects of chronic low-level intestinal colonisation
are unknown.
A link between AE bacteria and carcinogenesis is provided by
Citrobacter rodentium, which causes transmissible colonic hyperplasia
[12], reduces the latent period in appearance of chemically
induced tumours [13], and promotes colonic adenoma formation
in mice [14]. Based on such findings it has recently been suggested
that signals delivered by AE bacteria might promote cancer by
exacerbating defects in oncogenic pathways in human colonic
epithelial tissue [15]. The AE process is dependent on the
expression of intimin and translocation of bacterial effector
proteins into the host cell via a bacterial type-III secretion system.
The genes that encode the secretion system, translocator proteins,
several effector proteins and intimin are located in the bacterial
locus of enterocyte effacement (LEE) pathogenicity island [16].
The EspB protein is secreted by this system and is required for
translocation of effector proteins into the host cell. In EPEC that
carry mutant espB, effector protein translocation and AE do not
occur [17]. By the process of intimate attachment EPEC infection
induces host cell protein phosphorylation, cytoskeletal rearrange-
ment and signalling pathway activation [18,19]. Consequently the
expression of hundreds of host cell proteins with wide ranging
functions are up and down regulated subsequent to infection [20].
We hypothesised that the intracellular effects of EPEC infection
could promote susceptibility to cancer. For this reason we
investigated the effects of EPEC on the expression of DNA
mismatch repair (MMR) proteins. The DNA MMR system
maintains genomic stability by correcting DNA base pair
mismatches acquired from replication, recombination and chem-
ical damage. Failure of DNA MMR confers a mutator phenotype,
leading to the accumulation of thousands of somatic mutations in
DNA microsatellite sequences, a state termed microsatellite
instability (MSI). Inactivating mutations of the DNA MMR genes
MSH2 and MLH1 are the causative genetic feature of Hereditary
Non-Polyposis Colorectal Cancer and also occur in up to 15% of
sporadic colorectal cancers [21]. Another common mode of
mismatch repair gene inactivation is DNA methylation. In
sporadic colorectal tumours that present with loss of MLH1
expression, it is often MLH1 promoter hypermethylation that is
responsible for gene silencing [22]. It has been suggested that
because MLH1 silencing leads to colorectal cancer characterised
by MSI, MLH1 silencing is likely to be a relatively early event in
carcinogenesis [23].
Materials and Methods
Ethics Statement
Ethical approval for the use of human tissue was provided by
the NHS Lothian Research Ethics Committee. All information
pertaining to subjects and all human samples were used in
compliance with UK legislation.
Bacterial strains and culture conditions
Wild-type (wt) EPEC, strain E2348/69 and mutant (mut) EPEC
UMD864 [E2348/69 D48-759 espB1] [17] stocks were maintained
on MacConkey agar supplemented with crystal violet, sodium
chloride, 0.15% bile and 0.05% nalidixic acid (all Sigma-Aldrich,
Steinheim, Germany). Overnight cultures were grown from single
colonies inoculated into Luria Bertani (LB) broth and incubated at
37uC in an orbital shaker.
Cell lines and culture conditions
Human colorectal cancer cell lines HT29 and SW480 were
obtained from The European Collection of Cell Cultures
(ECACC). Cells were grown in Roswell Park Memorial Institute
(RPMI) 1640 media containing L-glutamine 300 g/L (Gibco/
Invitrogen, Paisley, UK), supplemented with 5% fetal calf serum
(Labtech/Biosera, Sussex, UK) referred to as R5 media. Stock
cells were grown as adherent monolayers in 75 cm2 cell culture
flasks (Corning/Costar, High Wycombe, UK) and maintained at
37uC in a humidified atmosphere of 5% CO2 in air.
In vitro co-culture
Initial co-culture experiments were performed with HT29 cells
grown to 90–100% confluency in 75 cm2 cell culture flasks.
Overnight EPEC cultures were directly inoculated into the cell
culture medium 1 in 100 and flasks were incubated at 37uC in a
humidified atmosphere of 5% CO2 in air. After 3 h, media was
removed from flasks, cells were washed three times with RPMI
media and fresh R5 media was added. Mutant EPEC infected cells
were re-inoculated with overnight mutant EPEC culture to replace
non-adherent bacteria lost during the washing process. The wash
cycle was repeated every 3 h for a total time-course of 12 h*.
Uninfected controls were either maintained for 12 h without
washing or were washed every 3 h in the same way as infected cells.
Cells that were allowed to recover from infection were initially co-
cultured with wild-type EPEC for 9 and 12 h (as described above)
then washed three times with RPMI media and treated with R5
media supplemented with penicillin 200,000 u/L, streptomycin
200 mg/L and gentamicin 100 mg/L (all Gibco/Invitrogen,
Paisley, UK) for 36–39 h. Cells used for later co-culture
experiments were grown in 10 cm diameter cell culture dishes
holding glass cover-slips. For these experiments we introduced a
bacterial pre-culture step. Prior to co-culture, overnight EPEC
cultures were inoculated into warmed R5 media (1 in 50 dilution)
and incubated for 1–1.5 h at 37uC to activate the bacteria [24]. The
infected R5 media was then added directly to the cells. After co-
culture cells adherent to cover-slips were fixed in paraformaldehyde
4% in PBS and used for immunofluorescence, cells adherent to the
dish provided protein for western blotting. [*Subsequent to these
experiments we noted that a change in fetal calf serum (to a different
supplier) affected bacterial growth during co-culture, but that a
minor adjustment of the washing schedule yielded the same results.]
Immunoblot analysis
Whole cell protein extracts were resolved through pre-cast 4–
12% gradient/10% Novex-NuPAGE gels (Invitrogen, Paisley,
UK) or 10% sodium dodecyl sulphate/polyacrylamide gels and
transferred to Hybond P membranes (GE Healthcare Biosciences,
Bucks, UK). Protein levels could not be equalised via conventional
densitometry due to the presence of bacterial protein in some
samples. Therefore, levels were equalised via successive western
blots with reference to beta-actin and proliferating cell nuclear
antigen (PCNA) band intensities, coumassie blue staining was also
used to aid equal protein loading. All antibodies were diluted in
E. coli and Colon Cancer
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tris-buffered saline with Tween-20 0.2% (TBST) containing 5%
powdered milk. Anti-MSH2 Ab-2/FE11 (Calbiochem/Merck,
Nottingham, UK) 1:500, anti-MLH1 (BD Biosciences, Oxford,
UK) 1:1000, anti-beta-actin AC-15 (Sigma-Aldrich, Steinheim,
Germany) 1:5000 and Anti-PCNA C-20 (Santa-Cruz Biotechnol-
ogy, CA) 1:1000 primary antibodies and peroxidase conjugated
secondary antibodies were applied for 30 minutes–2 hours or
overnight. Proteins were detected using ECL PlusH chemilumi-
nescence detection system, membranes were exposed to Hyperfilm
(GE Healthcare Biosciences, Bucks, UK).
Immunofluorescence staining of cells
Fixed cells were washed with PBS, permeabilised with Triton-X-
100 0.1% in PBS and blocked with BSA 3% and Tween-20 0.2% in
PBS for 1 hour. Cells were then washed with Tween-20 0.2% in
PBS (PBST) and incubated with primary antibody solutions for 1 h.
After washing with PBST, cells were incubated with secondary
antibody solutions for 30 minutes. Finally, cells were washed PBST
and mounted onto microscope slides with Vectasheid mounting
medium with DAPI (Vector Laboratories, Cambridge, UK). All
antibodies were diluted in PBST. The primary antibodies used were
anti-MSH2 1:200, anti-MLH1 1:200, anti-PCNA 1:500 (as in
immunoblots), anti-cytochrome c 1:500, anti-MTCO2 (both
Abcam, Cambridge, UK) 1:1000, Anti-E. coli (Europa Bioproducts,
Cambridge, UK) 1:2000. Secondary antibodies used were Alexa-
fluor 488 anti-mouse 1:1000 and Alexa-fluor 594 anti-sheep and
anti-rabbit 1:1000 (all Invitrogen Molecular Probes, OR). Cells
undergoing late stage apoptosis/necrosis were identified based on
labelling of DNA strand breaks (TUNEL technology) using an In
Situ Cell Death Detection Kit (Roche Diagnostics, Mannheim,
Germany) according to the manufacturers instructions, and
visualised via fluorescence microscopy. Percentages of TUNEL
positive cells were calculated by counting at least 400 cells from each
experimental condition (n= 3). Positive control cells were treated
with DNAse (Qiagen, Crawley, UK). Uninfected HT29 cells were
treated with etoposide 1 uM (Sigma-Aldrich, Steinheim, Germany)
for 2 hours, followed by 6 hours in R5 media, to act as positive
controls for apoptosis via cytochrome c staining.
Ex vivo tissue
The tissue co-culture protocol was adapted from published in
vitro organ culture (IVOC) methods [25–27]. After securing written
informed consent, full thickness sections of normal transverse
colon tissue were removed from three adult patients undergoing
colectomy (due to rectal or endometrial cancer) at the Western
General Hospital, Edinburgh. The mucosa was separated from the
muscularis, washed in sterile saline and transferred to the
laboratory in R5 media supplemented with nalidixic acid
50 mg/L. In the laboratory, tissue was washed three times in
warmed PBS, cut into approximately 2 cm2 pieces and placed
(luminal side upwards) onto pieces of metal gauze within central-
well tissue culture dishes containing warmed R5 media with
nalidixic acid 50 mg/L. Uninfected control tissue was fixed
immediately after washing with PBS. Tissue samples were placed
in a pressurised chamber gassed with 95% O2 5% CO2 and
maintained at 37uC. After a 1 h equilibration period tissue that
was to be infected received 200 ul of wild-type EPEC culture
(overnight culture diluted 1:50 in R5 media and activated at 37uC
for 1–2 h) added directly to the mucosal surface. After 4 h, tissues
were removed from culture dishes, washed thoroughly with
warmed PBS and placed back into culture dishes with fresh R5
media. This washing process was repeated every 2–3 h. After a
total co-culture period of 12 h, tissue was removed from culture,
washed three times in PBS and fixed overnight in 4% buffered
formalin. Tissue was embedded in paraffin and sections were cut
for immunofluorescence staining.
Adenocarcinoma tissue
Formalin fixed, paraffin embedded tissue sections were supplied
by the Department of Histopathology, University of Edinburgh.
Sections of normal and adenocarcinoma tissue from 20 colorectal
cancer patients were used. Sections were cut to 3 mm for
immunofluorescence staining and 20 mm for PCR.
PCR
Paraffin embedded tissue sections were subjected to proteinase
K digestion, then phenol chloroform extraction of DNA followed
by ethanol precipitation in the presence of yeast transfer RNA.
Primers for eae were: forward 59 GTG ACG ATG GGG ATC
GAT and reverse 59 GGC TCA ATT TGC TGA GAC CAC
GGT T (product 110 bp) or 59 ACG GCT GCC TGA TAA TGT
T (150 bp product). PCR cycle conditions: 94uC 2 min, (94uC
30 sec, 58uC 30 sec)630 cycles.
Immunofluorescence staining of human tissue
Tissue sections were de-paraffinised with xylene and alcohol.
Antigen retrieval was carried out by heating slides in citrate buffer
(pH 6.4) for 15 min. Tissue was permeablised with Triton-X-100
1% in PBS and blocked with BSA 0.2% in PBS for 1 h. Anti-E. coli
(Europa Bioproducts, Cambridge, UK) 1:2000, anti-ezrin (BD
Biosciences, Oxford, UK) 1:500 and anti-Ki67 (DAKO, Glostrup,
Denmark) 1:1000 primary antibodies were diluted in blocking
solution and incubated with sections for 45 minutes–2 h at room
temperature or overnight at 4uC. Alexa-fluor 488 and 594
fluorescent secondary antibodies were diluted 1:2000 in PBS and
incubated with sections for 30 minutes at room temperature.
Sections were mounted with Vectasheid mounting medium with
DAPI (Vector Laboratories, Cambridge, UK). In ex vivo tissue the
possibility of cross staining endogenous E. coli was excluded by
ensuring that matched, adjacent tissue (from the same patient) was
completely negative for E. coli via immunofluorescence.
Image capture & Quantitative image analysis
Fluorescent images were captured using either a Zeiss Axioskop
20 fluorescence microscope (Zeiss, Luton, UK) using Smartcap-
ture software (Digital Scientific, Cambridge, UK) or a Zeiss
Axioplan II fluorescence microscope (Zeiss, Luton, UK) using
IPLab Spectrum software (Scanalytics Corp, Fairfax, VA). Image
analysis was performed using in-house scripts written for IPLab.
Briefly, software calculated the nuclear staining intensities for the
proteins of interest in individual cells. The individual intensity
values for over 300 cells were counted for each experimental
condition. The entire experiment was repeated on three separate
occasions. For MSH2 and MLH1, cells with staining intensity
values below 5% of the maximum intensity (measured in
uninfected controls) were categorized as MMR protein deficient.
This is a categorization reflects the fact that low MMR protein
expression levels (,10%) are required for a deficiency in MMR
function [28]. The same categorization (i.e. above or below 5% of
maximum intensity) was arbitrarily applied to PCNA staining.
Results
EPEC infection caused downregulation of DNA mismatch
repair proteins in vitro
To investigate the effects of prolonged EPEC infection on
MMR protein expression, we established an extended time-course
E. coli and Colon Cancer
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co-culture model. During the course of in vitro co-culture
experiments EPEC causes cultured cells to detach from culture
vessels by disrupting focal adhesions, adherens junctions and tight
junctions [29–31]. Hence, EPEC induced loss of adhesion
fundamentally limits the time-course of co-culture experiments.
By using confluent cell monolayers and washing cells every
3 hours (to remove excess non-adherent bacteria) we were able to
extend the co-culture time-course to 12 hours. Although some cell
detachment did occur during this time-course, the majority of cells
remained adherent at 12 hours; beyond this time-point loss of
adherence made co-culture impractical. Figure 1a demonstrates
the adherence patterns of wild-type and mutant EPEC after in vitro
co-culture. Wild-type EPEC attach intimately to host cells and
show widespread distribution across the cell monolayer after
12 hours. The mutant EPEC (with an internal deletion in the gene
encoding EspB, a key component of the type III bacterial secretion
system) are unable to attach intimately, but adhere in localised
clusters using bundle forming pili.
Immunoblots revealed a marked reduction in MSH2 and
MLH1 protein expression (relative to actin and PCNA which
were both used as loading controls) in HT29 cells after 9–
12 hours co-culture with wild-type EPEC. In contrast, uninfected
cells and cells infected with non-intimately attaching mutant
EPEC retained strong MMR protein expression (Figure 1b).
Treating cells that had been infected with wild-type EPEC for 9–
12 hours with antibiotics allowed them to recover from infection
and survive long term. After only 36–39 hours antibiotic
treatment, infected cells were able to recover MMR protein
expression to pre-infection levels (Figure 1c). SW480 cells showed
a similar reduction on MSH2 and MLH1 in response to EPEC
(Figure 1d), indicating that this effect was not limited to a single
cell line.
Figure 1. Co-culture of human colorectal cell lines with EPEC in vitro. Immunofluorescence staining for E. coli (red) and DAPI nuclear staining
(blue) shows the adherence patterns of wild-type (E2468/69) and mutant (UMD864) EPEC (a). Immunoblot analysis of DNA mismatch repair protein
expression in human colorectal cancer cell lines co-cultured with EPEC: HT29 cells were either uninfected (2) or co-cultured with wild-type (+wt) or
mutant (+mut) EPEC for 3–12 hours (b). HT29 cells were either uninfected or co-cultured with wild-type EPEC for 9 or 12 hours then treated with
antibiotics for 36–39 hours (*) to remove infection (c). SW480 cells were either uninfected or co-cultured with wild-type or mutant EPEC for 9 or
12 hours (d). EPEC strain UMD864 does not express EspB, a protein required for a functional type III secretion system. Scale bar = 10 mm.
doi:10.1371/journal.pone.0005517.g001
E. coli and Colon Cancer
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As an alternative method to quantify the loss of MMR protein
expression, we performed immunofluorescence staining combined
with quantitative image analysis. Images of immunofluorescent
stained uninfected and mutant infected HT29 and SW480 cells
show that MSH2 and MLH1 expression was strong and localised
to the nuclei. After 9 hours infection with wild-type EPEC, MSH2
and MLH1 expression was markedly reduced in some cells but
retained in others. After 12 hours infection with wild-type EPEC
the majority of cells had very low MMR protein expression.
PCNA staining was used as a positive control for image analysis of
nuclear staining. In comparison to MMR proteins levels PCNA
expression levels remained relatively constant in the presence of
EPEC infection (Figure 2a & b). Quantitative image analysis of
immunofluorescence stained HT29 and SW480 cells confirmed
that wild-type EPEC infection induced a marked reduction in
MSH2 and MLH1 expression (Figure 3a & b). Image analysis
graphs show that up to 90% of HT29 and SW480 cells were
MMR protein deficient after 12 hours infection with wild-type
EPEC. MMR protein downregulation was more rapid in SW480
cells (i.e. more MMR protein deficient cells present after 9 hours
infection), but more complete in HT29 cells after 12 hours
infection. Infection with the non-attaching and effacing mutant
EPEC had very little effect on MMR protein expression after
9 hours, with a small increase in the number of MMR deficient
cells after 12 hours. This demonstrates that MMR protein
downregulation was predominantly dependent on translocation
of effector proteins from bacteria to host cell and/or signalling due
to intimate attachment. PCNA was used as a positive control for
image analysis and its expression remained relatively constant in
comparison with the MMR proteins.
EPEC induced mismatch repair protein downregulation
was not associated with apoptosis/necrosis
Activation of protease enzymes during apoptosis results in the
degradation of many intracellular proteins, including DNA MMR
proteins [32]. We therefore investigated whether the effects of
EPEC on MMR protein expression were related to apoptosis or
necrosis. TUNEL staining demonstrated that most cells displaying
EPEC induced MMR protein (MLH1) downregulation had not
entered late stage apoptosis/necrosis (Figure 4a). Counts of
TUNEL positive and negative cells show that although wild-type
(and to a lesser degree mutant) EPEC infection caused an increase
in the number of cells undergoing apoptosis/necrosis, this change
was relatively small compared with the number of cells showing
MMR protein downregulation (Figure 4b).
It was possible that infected cells had not had sufficient time to
reach late stage apoptosis as measured by the TUNEL assay, so to
identify cells undergoing the early stages of apoptosis we analysed
cytochrome c distribution [33]. In uninfected cells and cells
infected with wild-type EPEC for 12 hours, cytochrome c was
distributed in discrete cytoplasmic regions (mitochondria). In cells
treated with etoposide as a positive control, cytochrome c
distribution was diffuse. This demonstrates that the release of
cytochrome c from mitochondria was occurring in these cells, an
indicator of commitment to the early stages of apoptosis. In
addition, MLH1 expression was strong in both uninfected and
etoposide treated cells, but absent in cells infected with EPEC for
12 hours (Figure 4c). Cytochrome c distribution was confirmed to
be limited to the mitochondria in both uninfected and EPEC
infected cells (but not in etoposide treated cells) by staining
mitochondrial marker MTCO2 (Figure 4d). Cytochrome c
staining was also performed on cells infected with wild-type EPEC
for 9 hours and showed the same distribution as in uninfected cells
and cells infected for 12 hours (not shown).
Co-culture of ex vivo adult human colonic mucosa with
EPEC
EPEC is the most prevalent form of AEEC found in man,
EPEC has been reported to adhere to adult colon tissue [34], but it
has not been previously reported whether EPEC are capable of
entering colonic crypts. Colonic tumours are thought to develop
from proliferative epithelial cells found within colonic crypts [35].
We wished to investigate whether EPEC could enter colonic crypts
and attach to cells in the proliferative compartment. Normal
colonic mucosa was removed from three adults; mucosal strips
from each patient were either uninfected or co-cultured with wild-
type EPEC for 12 hours. Fixed mucosa sections were probed by
immunofluorescence and the number of crypts containing E. coli
was counted. In total, E. coli were detected in 195 of 1928 (10.1%,
range 4.8%–14.2%) crypts in tissue that had been co-cultured with
EPEC. In contrast, no E. coli were found in 1797 crypts examined
from uninfected tissue (P,0.001, chi square test, two tails). It was
noted that E. coli did not show widespread adherence to the surface
epithelium of the mucosa (i.e. outside the crypts). Within
individual crypts the number of bacteria (per 3 mm cross section)
varied from single cells to colonies of tens and in some cases up to
approximately one hundred bacteria. Successive sections demon-
strated that bacterial colonies spread along the width as well as the
length of the crypts. Crypts that were positive for E. coli were
distributed in a random fashion throughout the tissue cross-section
and did not therefore occur due to lateral infection.
To assess whether EPEC were closely associated with the apical
surface of crypt epithelial cells we stained mucosa sections with
ezrin. Ezrin is a structural protein that anchors the cytoskeleton to
the plasma membrane and is found at sites of EPEC induced AE
lesions [36]. Staining of ezrin confirmed that EPEC was often
closely associated with (and potentially intimately attached to) the
apical surface of crypt epithelial cells (Figure 5). It can also be seen
from Figure 5 that EPEC were found in the mid-region of the
crypts. This distribution overlaps with the proliferative region of
the crypts [37]. These results demonstrate for the first time that
EPEC are able to enter crypts of the adult human colon, penetrate
into the proliferative compartment and associate with crypt
epithelial cells.
Analysis of human colorectal adenocarcinomas for
mucosa-associated E. coli and attaching and effacing E.
coli
Previous reports have demonstrated that E. coli are often found
attached to colonic adenocarcinomas; we wished to investigate this
association and assess whether AEEC strains were present.
Matched normal colonic mucosa and colonic adenocarcinoma
tissue from 20 patients was analysed for mucosa-associated E. coli
(by immunofluorescence) and the presence of eae (by PCR).
Mucosa-associated E. coli were identified in 3/20 samples (15%) of
normal mucosa, 0/20 (0%) samples tested positive for eae, whereas
10/20 (50%) of adenocarcinomas were positive for mucosa-
associated E. coli, 5/20 (25%) of which were eae positive (Figure 6a).
The increased frequencies of mucosa-associated E. coli and AEEC
on adenocarcinomas compared to normal tissue were statistically
significant (P,0.05 for both comparisons, Fisher’s Exact Test, two
tails). Mucosa-associated E. coli were clearly visible on the apical
surface of epithelial cells within tubulo-villus crypts of adenocar-
cinomas, as demonstrated by the example shown in Figure 6b.
The number of individual E. coli per adenocarcinoma section
ranged from tens to tens of thousands. Figure 6c is a representative
PCR result, which shows that the adenocarcinoma shown in
Figure 6b tested positive for eae, but that normal colonic mucosa
E. coli and Colon Cancer
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from the same patient did not. Formalin fixed, paraffin embedded
sections of human ex vivo colon mucosa that were either uninfected
or infected with wild-type EPEC were used as additional negative
and positive PCR controls respectively.
Discussion
Previous studies have established that mucosally adherent E. coli
are often present on colonic tissue from colorectal cancer patients
[4,5]. The results of the present study strongly support this
association. In addition, this study demonstrates for the first time
an association of AEEC strains with human colorectal adenocar-
cinomas. Furthermore, we uncovered a mechanism by which
AEEC might contribute to the development of colorectal
carcinoma by downregulating mismatch repair proteins that
protect cells against accumulating mutations. EPEC strains are
the predominant AEEC strains identified in human subjects [8–
10]. As EPEC screening is no longer performed in developed
countries there is currently a lack of data on the carriage of EPEC
among the healthy adult population of these countries. Presently,
studies on the prevalence of EPEC infection focus on children, and
show that up to 10.9% of asymptomatic (i.e. healthy) children in
developed countries carry EPEC [10]. In the sample of colorectal
cancer patients we tested, AEEC were identified in 25% of cancer
tissue specimens, but in no specimens of normal tissue.
A limitation of the present study is the relatively small number
of patients tested (n = 20), resulting in wide confidence intervals
around this estimate (6% and 43%). Despite this limitation, the
Figure 3. Quantitative image analysis of DNA mismatch repair protein immunostaining in human colorectal cancer cell lines co-
cultured with EPEC. HT29 (a) and SW480 cells (b) were either uninfected (2) or co-cultured with wild-type (+wt) or mutant (+mut) EPEC for 9–
12 hours. Fixed cells were probed for MSH2, MLH1 and PCNA by immunofluorescence. Digital images were quantitatively analysed for nuclear
staining intensity of the proteins of interest. According to staining intensity values, individual cells were categorised as having an intensity value
greater than or equal to 5% of the maximum staining intensity (as measured in uninfected controls) or less than 5% of the maximum staining
intensity. Cells with MSH2 or MLH1 staining below 5% of the maximum were classed as MMR protein deficient. The entire experiment was performed
on three separate occasions for each cell line, error bars represent standard error of mean.
doi:10.1371/journal.pone.0005517.g003
Figure 2. Immunofluorescence staining of DNA mismatch repair proteins in human colorectal cancer cell lines co-cultured with
EPEC. HT29 (a) and SW480 cells (b) were either uninfected (2) or co-cultured with wild-type (+wt) or mutant (+mut) EPEC for 9–12 hours. Fixed cells
were probed for MSH2, MLH1 (both green) and PCNA (red) by immunofluorescence, nuclei were counterstained with DAPI (blue). Scale bar = 10 mm.
doi:10.1371/journal.pone.0005517.g002
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result was statistically significant and suggests that a substantial
percentage of adults with colorectal cancer carry AEEC. Studies
on additional populations of cancer patients (along with healthy
controls) are required to substantiate this association. Another
limitation was the use of paraffin sections, which made it
impossible to isolate bacteria from tissue samples. Future studies
Figure 4. EPEC induced mismatch repair protein downregulation was not associated with apoptosis/necrosis. HT29 cells either
uninfected (2) or co-cultured with wild-type EPEC (+wt) for 9–12 hours were stained (red) using an in vitro cell death (TUNEL) detection kit, MLH1 was
simultaneously stained (green) and nuclei were counterstained with DAPI (blue) (a). HT29 cells were either uninfected (2) or co-cultured with wild-
type (+wt) or mutant (+mut) EPEC; TUNEL positive and negative cells were counted. Fixed HT29 cells treated with DNAase (to induce DNA strand
breaks) were used as positive controls, error bars represent standard error of mean (n = 3) (b). HT29 cells were stained for MLH1 (green) and
cytochrome c (red) (c) or for cytochrome c (red) and the mitochondrial marker MTCO2 (green) (d). Cells treated with etoposide for 2 h were positive
controls for early apoptosis. Scale bar = 10 mm.
doi:10.1371/journal.pone.0005517.g004
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Figure 5. Co-culture of ex vivo adult human colonic mucosa with EPEC. Sections of colonic mucosa were removed from surgical patients and
co-cultured with wild-type EPEC for 12 hours, then fixed in buffered formalin and embedded in paraffin. Images show examples of tissue sections
stained by immunofluorescence for E. coli (red) and ezrin (green) as a marker of the cell surface and DAPI (blue). Scale bar = 10 mm.
doi:10.1371/journal.pone.0005517.g005
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of cancer patients should therefore utilise fresh tissue, from which
the specific bacterial strains, serotypes, clonal lineages and
virulence factors could be identified.
Though we have identified an association between AEEC and
colorectal cancer, it is presently unknown if this association is
causal. The difference in AEEC distribution between normal and
adenocarcinoma tissue may be due to the affinity of EPEC for
surface residues on tumour cells. Surface antigens of fetal and
tumour cells display some homology, leading to the suggestion by
Martin et al. (2004) that adherent E. coli bind to ‘oncofetal’ surface
antigens created by altered mucosal glycosylation [4]. In addition
to improved binding affinity, the increased surface area of tumour
versus normal tissue also facilitates binding of far greater numbers
of adherent bacteria. This observation could also explain why
tumourigenesis may be of benefit to the bacteria, as tumours
seemingly provide an environment conducive to bacterial
adhesion and growth.
Previous studies that have employed co-culture of EPEC with
human intestinal tissue generally focus on bacterial adhesion
within the small intestine and use tissue removed from children
[26,38–40]. Results of a recent study show that EPEC strains are
able to adhere to adult colon tissue but the culture method
employed did not reveal where the bacteria were bound [34]. A
key aspect of the present study was therefore to identify the sites of
EPEC adhesion within the adult colonic mucosa and specifically
whether EPEC entered colonic crypts. We found that EPEC
readily entered colonic crypts and attached to epithelial cells, often
in the mid-region of the crypts. The mid and lower sections of
colonic crypts contain undifferentiated proliferative epithelial cells.
Colorectal cancer is thought to arise from transformation of these
cells [35]. The washing procedures used during co-culture are
likely to have reduced the levels of surface mucus, potentially
facilitating the adhesion of bacteria. However, it was macroscop-
ically apparent that mucus was secreted from the ex vivo mucosa
throughout the co-culture time-course, and immunosections
illustrate that crypt goblet cells contain mucus after 12 hours co-
culture. EPEC were able to enter the crypts and attach to
epithelial cells despite this.
A potential explanation for the apparent affinity of EPEC for
crypt cells is the change in expression of surface glycoproteins
during cell migration from crypt to surface epithelium [41,42].
Within crypts, mitotically active, undifferentiated cells (in
similarity to fetal/cancer cells) express active glycosyltransferase
enzymes and acceptor sites that are glycoproteins with incomplete
polysaccharide chains [43,44]. A selective ability to bind to the
surface residues of these undifferentiated cells could explain the
affinity of EPEC for adenocarcinoma cells and the more severe
pathology of EPEC infection in the infant intestine. The abilities of
EPEC to enter crypts of the adult human colon and attach to crypt
epithelial cells are novel findings, and illustrate a potential niche
environment for EPEC in the adult colon that requires further
investigation.
Intimate attachment of EPEC to epithelial cells involves
injection of bacterial proteins into the host cell, resulting in up
Figure 6. Analysis of human colorectal adenocarcinomas and normal colorectal tissue for attaching and effacing E. coli. Paraffin
embedded sections of adenocarcinoma and matched normal tissue from 20 patients were probed for E. coli by immunofluorescence and for the
bacterial gene eae by PCR (*P,0.05, Fisher’s Exact Test, two tails) (a). Example of an adenocarcinoma with mucosa associated E. coli (red), nuclei
stained with DAPI (blue) (b) that tested positive for eae by PCR (c). Sections of ex vivo human colonic mucosa that were either co-cultured with (+) or
without (2) wild-type EPEC were used as additional controls for PCR. Scale bar = 10 mm.
doi:10.1371/journal.pone.0005517.g006
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and down regulated expression of a wide range of host cell proteins
[20]. We hypothesised that the effects of EPEC infection on the
host cell could promote susceptibility to cancer. One candidate
target for disruption is DNA mismatch repair (MMR), a system
that maintains genomic stability by correcting DNA base pair
mismatches. Inactivating mutations of the DNA MMR genes
MSH2 and MLH1 are a causative genetic feature of many
colorectal cancers.
In co-culture experiments with colorectal cell lines we observed
that wild-type EPEC caused a dramatic reduction in the
expression of the key MMR proteins MSH2 and MLH1. Despite
causing a marked downregulation of these proteins, wild type
EPEC infection was not associated with widespread induction of
apoptotic/necrotic mechanisms. This is a logical finding since
MMR proteins are involved in signalling DNA damage induced
apoptosis, deficiency of these proteins therefore suppresses
apoptosis [45]. We also demonstrated that cells infected for up
to 12 hours with wild-type EPEC were able to survive after
removal of infection. DNA replication in the absence of functional
DNA mismatch repair and DNA damage associated apoptotic
signalling would present an environment highly conducive to the
accumulation of mutations.
In mouse models, lack of functional DNA MMR causes
increased spontaneous mutation frequency rates in all parts of
the colon [46] and enhances somatic mutation of Apc and p53;
genes mutated in the majority of colorectal cancers [47]. It is
therefore possible according to our current hypothesis, that EPEC
infection could cause a transient mismatch repair inactivation that
may drive carcinogenesis by promoting somatic mutations.
Cancers evolving through this hypothetical pathway may therefore
present with some degree of microsatellite instability or microsat-
ellite alterations in cancer relevant genes (e.g. APC, p53) even if
they are not categorised as being microsatellite unstable. It is
notable that some microsatellite stable colorectal tumours do
indeed present with frameshift mutations in repetitive regions of
APC [48]. Whether EPEC infection could be responsible for
promoting such mutations remains to be elucidated - analysing this
subset of sporadic tumours for EPEC infection could help to
answer this question, though clearly an observed EPEC infection
may be independent of (and consequent to) the carcinogenic event.
More directly, probing tumours infected with EPEC for MSI
would help to establish whether or not infection could promote
this genetic aberration.
It should be noted that MMR failure also promotes mutations in
non-repetitive regions of DNA (in addition to microsatellite
sequences), as shown by studies on mutation spectra in human
cells [49–52]. Analysis of mutation spectra in yeast also showed
that MMR mutants (msh2, msh6, mlh1 and pms1) had increased
frameshift mutation rates in non-repetitive regions compared to
wild-type [53]. Microsatellite instability is not therefore the sole
result or indicator of DNA MMR failure, and transient MMR
inactivation (e.g. via EPEC infection) could promote mutations in
cancer relevant genes without causing MSI.
This study identifies a striking similarity between EPEC and the
carcinogenic bacterium Helicobacter pylori, which has also been
found to downregulate MSH2 and MLH1 expression in human
cell lines [54]. Although not classed as an AE bacterium, H. pylori
attach to and interact intimately with gastric epithelial cells [55,56]
similarity to EPEC, some H. pylori strains also have a secretion
system used to translocate effector proteins (such as CagA) into
host cells [57]. It is notable that H. pylori strains that carry the cag
pathogenicity island (required for the bacterial type-IV secretion
system) have increased ability to cause cancer versus cag negative
strains [58].
Quantitative immunofluorescence demonstrated that MMR
protein downregulation occurred more rapidly in SW480 cells
versus HT29 cells. SW480 cells show less features of differentiation
(e.g. enterocytic differentiation, cell polarity) than HT29 cells [59].
We speculate that the reason EPEC is able to initiate its effects
more rapidly in SW480 cells may be because it can bind more
efficiently to undifferentiated cells. This property would help to
explain the apparent binding affinity of EPEC for cells that are
‘less differentiated’ in vivo i.e. adenocarcinoma, fetal and possibly
proliferative crypt cells. It is logical that EPEC would target more
immature cells when invading a host. Firstly, these cells are likely
to live for longer than differentiated cells (especially in the colon
where cell turnover is rapid), providing a longer lasting binding
site. Secondly, it is possible that the molecular and cellular
consequences of EPEC infection are more easily effected in
undifferentiated cells, where cell fate is yet to be determined.
In the present study we have characterised and quantified the
effect of EPEC infection on DNA MMR proteins expression in
vitro. The exact mechanisms responsible for this effect were beyond
the remit of the present study and require further investigation.
We have demonstrated that a mutant EPEC strain (lacking EspB,
a key component of the bacterial type-III secretion system) did not
induce significant MMR protein downregulation. This indicates
that EPEC induced MMR downregulation was dependent on
translocation of bacterial effector proteins and/or intimate
attachment. EPEC secreted effector proteins have been shown to
target specific host proteins and organelles; e.g. EspF targets tight
junction proteins and mitochondria [31,60]. The time-scale of
EPEC induced MMR protein downregulation suggests that MMR
protein degradation may be occurring in the host cell. Degrada-
tion of MMR proteins can occur via proteosomal degradation
subsequent to ubiquitination [61], a process that may be targeted
by effector proteins. Co-culture experiments with a panel of
mutant EPEC strains (with specific bacterial effectors knocked out)
would help uncover the effector protein(s) responsible for effects on
MMR. It will also be important to investigate whether other
AEEC strains are able to induce MMR protein downregulation.
Of particular interest are atypical EPEC strains, which are of
increasing importance in developed countries.
Regulation of MMR protein can occur at transcriptional level
by a number of pathways and it is possible that transcriptional
silencing also contributes to EPEC induced MMR protein
downregulation. Microarray analysis of HT29 cells revealed a
2–4 fold reduction in RNA levels of mismatch repair genes MSH2,
MLH1 and MSH6 in wild-type EPEC infected cells (but not espB
mutant EPEC infected cells) versus uninfected controls (unpub-
lished data). In cancer cell lines, suppression of DNA MMR has
been observed via inhibition of E2F transcriptional activity by Bcl-
2 [62]. Bcl-2 function is regulated by phosphorylation, mediated
by Protein Kinase Ca (PKCa) [63]. EPEC infection increases
membrane bound PKCa activity and the PKCa content of cancer
cell membranes [64]. This suggests that EPEC-induced activation
of PKCa might result in phosphorylation of Bcl-2, thus promoting
cell survival and inhibiting the transcription of MMR genes. EPEC
induced MMR protein downregulation provides a mechanism by
which infected cells could have a significantly increased suscep-
tibility to mutation. The consequences of EPEC induced MMR
protein downregulation on spontaneous and induced mutation
frequency rates therefore requires investigation.
The findings of this study suggest that chronic EPEC infection
in asymptomatic adults could promote tumourigenesis within the
colon by influencing the molecular biology of colonic epithelial
cells. In support of this idea, we have identified a high incidence of
AEEC in patients with colonic adenocarcinoma and an association
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between AEEC and tumours in these patients. The role of EPEC
in colonic tumourigenesis therefore warrants further investigation;
of particular interest is the prevalence of EPEC infection in healthy
adults versus those with colonic adenomas and carcinomas.
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